Business / Finance

RSS

Asterias Biotherapeutics simplifies capital structure through previously announced Asset Swap with BioTime

Asterias Biotherapeutics, Inc., a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today simplified its capital structure through the previously announced Asset Swap with BioTime, Inc.

17 Feb 2016

CTI BioPharma announces Q4 and FY 2015 earnings

CTI BioPharma Corp. today reported financial results for the fourth quarter and full year ended December 31, 2015.

17 Feb 2016

Aytu BioScience announces business strategy update and Q2 financial results

Aytu BioScience, Inc., a specialty healthcare company focused on developing treatments for urological and related conditions, provided today an overview of its business and growth strategy, as well as its financial results for the quarter ended December 31, 2015.

17 Feb 2016

Helsinn, Mundipharma sign distribution, license and supply agreements for anamorelin

Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announce that they have entered into distribution, license and supply agreements with Mundipharma and its network of independent associated companies granting exclusive rights to anamorelin in Norway, Finland, Sweden, Denmark and Iceland.

16 Feb 2016

Sphere Medical's new manufacturing facility for Proxima blood gas analyser opens in St. Asaph, Wales

Sphere Medical, an innovator company in critical care monitoring and diagnostics equipment, has opened its new commercial production facility in St. Asaph, Wales.

15 Feb 2016

Protein Sciences, UNIGEN agree to supply Flublok influenza vaccine for the U.S. market from Japan

Protein Sciences Corporation (Meriden, CT and Pearl River, NY) and UMN Pharma Inc. (Akita, Akita prefecture, Japan) announced today that Protein Sciences and UNIGEN Inc., a joint venture of UMN and IHI Corporation (Koto-ku, Tokyo, Japan), entered into an agreement to source bulk Flublok influenza vaccine from Japan for the U.S. market.

12 Feb 2016

Apellis Pharmaceuticals completes $47.1M Series D preferred stock financing

Apellis Pharmaceuticals, Inc., today announced that it has completed a $47.1 million Series D preferred stock financing, co-led by new investors Cormorant Asset Management, Hillhouse Capital Group and venBio Global Strategic Fund, joining existing investors Morningside Venture Investments, AJU IB Investment, and Epidarex Capital.

12 Feb 2016

Neurocrine Biosciences reports net loss of $29.3 million for fourth quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter and year ended December 31, 2015.

12 Feb 2016

ASTRO encourages policymakers to increase financial support for cancer research in FY 2017 Budget

The American Society for Radiation Oncology commends the proposed investment in cancer-related research announced in the Fiscal Year 2017 Budget released yesterday by the White House.

12 Feb 2016

FDA requests $5.1 billion budget for FY 2017 to protect and promote public health

The U.S. Food and Drug Administration is requesting a total budget of $5.1 billion to protect and promote the public health as part of the President's fiscal year (FY) 2017 budget – an eight percent increase over the enacted budget for FY 2016.

10 Feb 2016

Landauer's revenues decrease 2.7% to $36.5 million in first fiscal quarter of 2016

Landauer, Inc., a recognized leader in personal and environmental radiation measurement and monitoring, outsourced medical physics services and high quality medical consumable accessories, today reported financial results for its fiscal 2016 first quarter ended December 31, 2015.

9 Feb 2016

Wayne State inks exclusive license agreement with TRImaran Pharma for novel class of drugs

Wayne State University recently entered into an exclusive license agreement with TRImaran Pharma Inc. for a class of novel drugs developed at Wayne State University that aims to offer hope in the treatment of post-traumatic stress disorders (PTSD), depression, ADHD and other neurological disorders.

9 Feb 2016

Study: Prior surgical abortion appears to increase risk of later preterm birth

Surgical methods used in a common form of abortion or to clear the womb after a spontaneous miscarriage appears to significantly increase the risk of a later preterm birth, say researchers at Thomas Jefferson University who analyzed 36 studies that enrolled more than 1 million women.

4 Feb 2016

Cell Therapy Catapult becomes Cell and Gene Therapy Catapult

The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announces the official change of its name to the Cell and Gene Therapy Catapult.

4 Feb 2016

Cantel Medical to buy Sterility Assurance Monitoring Products division of NAMSA for $13.5 million

CANTEL MEDICAL CORP., has entered into a definitive agreement with North American Science Associates, Inc. to acquire NAMSA's Sterility Assurance Monitoring Products division for $13.5 million in cash consideration. For the year ending December 31, 2015 this business had adjusted sales of $5.7 million.

4 Feb 2016

Edwards Lifesciences' global sales grow 8.6% to $671.1 million in fourth quarter 2015

Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended December 31, 2015.

3 Feb 2016

ST Asia signs licensing deal with PharmaMar to distribute new multiple myeloma drug in South East Asia

International biopharmaceutical company Specialised Therapeutics Asia will supply and distribute a novel oncology drug candidate throughout South East Asia, following an exclusive licensing deal with European pharmaceutical company PharmaMar.

3 Feb 2016

Hillenbrand acquires Red Valve for $131.9 million

Hillenbrand, Inc. has completed its previously announced acquisition of Red Valve Company, Inc. for a purchase price of $131.9 million in cash, including $3.3 million for related real estate.

2 Feb 2016

Aflac's total revenues decrease 3.5% to $5.3 billion in fourth quarter 2015

Aflac Incorporated today reported its fourth quarter results. Reflecting the weaker yen/dollar exchange rate, total revenues decreased 3.5% to $5.3 billion during the fourth quarter of 2015, compared with $5.5 billion in the fourth quarter of 2014. Net earnings were $730 million, or $1.71 per diluted share, compared with $703 million, or $1.57 per share, a year ago.

1 Feb 2016

FedMed gains access to Trovagene's Precision Cancer Monitoring tests and service

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that it has entered into an agreement with FedMed, Inc. establishing health benefit access to Trovagene's full line of Precision Cancer Monitoring (PCM) tests and services.

1 Feb 2016

Business / Finance

Asterias Biotherapeutics simplifies capital structure through previously announced Asset Swap with BioTime

CTI BioPharma announces Q4 and FY 2015 earnings

Aytu BioScience announces business strategy update and Q2 financial results

Helsinn, Mundipharma sign distribution, license and supply agreements for anamorelin

Sphere Medical's new manufacturing facility for Proxima blood gas analyser opens in St. Asaph, Wales

Protein Sciences, UNIGEN agree to supply Flublok influenza vaccine for the U.S. market from Japan

Apellis Pharmaceuticals completes $47.1M Series D preferred stock financing

Neurocrine Biosciences reports net loss of $29.3 million for fourth quarter 2015

ASTRO encourages policymakers to increase financial support for cancer research in FY 2017 Budget

FDA requests $5.1 billion budget for FY 2017 to protect and promote public health

Landauer's revenues decrease 2.7% to $36.5 million in first fiscal quarter of 2016

Wayne State inks exclusive license agreement with TRImaran Pharma for novel class of drugs

Study: Prior surgical abortion appears to increase risk of later preterm birth

Cell Therapy Catapult becomes Cell and Gene Therapy Catapult

Cantel Medical to buy Sterility Assurance Monitoring Products division of NAMSA for $13.5 million

Edwards Lifesciences' global sales grow 8.6% to $671.1 million in fourth quarter 2015

ST Asia signs licensing deal with PharmaMar to distribute new multiple myeloma drug in South East Asia

Hillenbrand acquires Red Valve for $131.9 million

Aflac's total revenues decrease 3.5% to $5.3 billion in fourth quarter 2015

FedMed gains access to Trovagene's Precision Cancer Monitoring tests and service

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Latest News